OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2024): Submission to First Decision: 6.3 weeks; Submission to Acceptance: 11.4 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Stem Cell Therapy
Submission Deadline:
December 30, 2018 (Closed)
Guest Editor
Luis Martinez, MD
President and CEO, Regenera Global, San Juan, 00926, Puerto Rico
Website | E-Mail
Research Interests: stem cell; cancer; regenerative medicine and cell therapy; preventive medicine; clinical research
About This Topic
Dear Colleagues:
The field of stem cell medicine is advancing at a rapid pace. Interestingly, this advancement has been, to a point, fueled by parallel pathways. On one end, point of care stem cell treatments offered in clinics, and under generally lax regulatory guidelines have served to provide much empirical data on the safety and possible applications of autologous stem cell treatments. On the other end, academic institutions, alongside pharmaceutical and biotech companies, have focused on studying the complex stem cell environment. The intention being the development of stem cell biological drugs that abide by the traditional regulatory channels and which utilize placebo controlled studies to demonstrate efficacy. Independently, these pathways are, more and more, converging on a compromise between obtaining robust data, and facilitating the regulatory process. The point is to accelerate patient access to these novel therapies.
If we look at aging as a failure of stem cells, then chronic degenerative diseases arise from our bodies inability to maintain proper repair mechanisms at the cellular level. With this in mind, this special issue will focus on the translational and current clinical applications of stem cell therapies as they relate to treating, stopping, or reversing the aging process and its complications.
We invite articles that contemplate, but are not limited to the following topics:
- Impact and modulation of telomere length on stem cell function and regenerative capacity
- The use of stem cells to treat frailty and aging
- Autologous vs. allogeneic stem cells for chronic degenerative diseases
- Stem cell dosing and administration routes
- Current approvals and coming of age indications for stem cells in medicine
- Mitochondrial function in stem cells and aging
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Open Access
Original Research
Abstract
Background: Stem cell technology is a promising research area with a potential to create effective therapies for many degenerative diseases. However, to apply stem cell technology, we need to be able to identify and understand mechanisms that distinguish healthy regeneration processes from [...]
|
Loren Pickart
and